Trials / Not Yet Recruiting
Not Yet RecruitingNCT06078839
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy: a Multicenter Randomized Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 778 (estimated)
- Sponsor
- Xu Li · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the therapeutic effect of nafamostat mesilate on patients with severe infection-related coagulation。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nafamostat mesilate | Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml) |
| DRUG | 5% glucose | Add 50ml of 5% glucose into a 50ml syringe |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2023-10-12
- Last updated
- 2023-10-12
Source: ClinicalTrials.gov record NCT06078839. Inclusion in this directory is not an endorsement.